Model‐based analysis reveals a sustained and dose‐dependent acceleration of wound healing by VEGF‐A mRNA (AZD8601)

J. Almquist, M. Rikard, M. Wågberg, A. C. Bruce, P. Gennemark et al. CPT: Pharmacometrics & Systems Pharmacology (PSP), 21 May 2020.


Intradermal delivery of AZD8601, an mRNA designed to produce vascular endothelial growth factor A (VEGF‐A), has previously been shown to accelerate cutaneous wound healing in a murine diabetic model. Here, we develop population pharmacokinetic and pharmacodynamic models aiming to quantify the effect of AZD8601 injections on the dynamics of wound healing. A dataset of 584 open wound area measurements from 131 mice was integrated from three independent studies encompassing different doses, dosing timepoints, and number of doses. Evaluation of several candidate models showed that wound healing acceleration is not likely driven directly by time‐dependent VEGF‐A concentration. Instead, we found that administration of AZD8601 induced a sustained acceleration of wound healing depending on the accumulated dose, with an ED50 of 92 µg. Simulations with this model showed that a single dose of 200 µg AZD8601 can reduce the time to reach 50% wound healing by up to 5 days.

Photo credits: Nic McPhee